Novel Targets for Precision Medicine for Cancer

Hellman Asaf, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research



Life Sciences and Biotechnology   


Cancer, Glioblastoma, Precision Medicine, Early detection, Cancer mutations, DNA methylation, AI

Current development stage

For Pharmaceutical development: TRL4 - PoC&Safety of candidate device or system is demonstrated in a defined lab or animal model



Cancers develop due to combinations of deleterious mutations in coding and regulatory sequences of particular genes. Current diagnostic, prognostic, and genome editing protocols are limited to tumors with mutations in gene coding sequences, thus inapplicable to a large fraction of common cancers. Applying a novel method, Prof. Hellman uncovered the regulatory sites underlying abnormal activity of the genes driving tumors, specifically glioblastoma initiation, and progression. The novel targets allow application of current and future protocols to an additional 75-80% of glioblastoma tumors which are currently untreatable.


Our innovation

Prof. Hellman constructed a methylation-centered strategy to map functional regulatory units across cancer gene domains. Using this method, he revealed a network of enhancers and silencers, cooperatively guiding tumor expression profiles. Transformed activity of key network components appeared as a major contributor to drive gene malfunction in human glioblastomas. This finding illuminates a mechanism driving the development of cancer and imply novel potential therapeutic targets.  



The appearance of tumors without coding-sequence mutations is a frequent, poorly understood phenomenon. Specifically, precision oncology protocols are inapplicable of treating 75-80% of human glioblastomas. The novel targets expand the applicability of current and future diagnostic and therapeutic protocols to the majority of tumors.   



Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME: